Holen Sie sich die Stockscreener-App
72.29
2.32%
-1.72
Handel nachbörslich:
73.30
1.01
+1.40%
Solventum Corp Aktie (SOLV) Neueste Nachrichten
Agree To Buy Solventum At $50, Earn 2.9% Annualized Using Options - Nasdaq
Revolutionary 5-Second Sterilization Test Transforms Hospital Efficiency - StockTitan
March 2025 DE Pearls for Your Practice - Dental Economics
Charles Schwab Investment Management Inc. Has $75.92 Million Holdings in Solventum Co. (NYSE:SOLV) - Defense World
Mutual of America Capital Management LLC Sells 461 Shares of Solventum Co. (NYSE:SOLV) - Defense World
Oppenheimer & Co. Inc. Has $272,000 Holdings in Solventum Co. (NYSE:SOLV) - Defense World
Reviewing Solventum (SOLV) and Its Rivals - Defense World
Solventum (NYSE:SOLV) Stock Price Expected to Rise, Morgan Stanley Analyst Says - Defense World
Solventum Co. (NYSE:SOLV) Shares Sold by US Bancorp DE - MarketBeat
Solventum Corp. stock falls Wednesday, underperforms market - MarketWatch
Morgan Stanley Adjusts Price Target on Solventum to $80 From $73, Maintains Equalweight Rating - Marketscreener.com
Solventum Co. (NYSE:SOLV) Stock Position Lifted by Bank of New York Mellon Corp - Defense World
Head-To-Head Contrast: Solventum (SOLV) vs. Its Peers - Defense World
Solventum Corp. stock falls Tuesday, underperforms market - MarketWatch
Solventum hires chief strategy officer out of Zimmer Biomet - Mass Device
Solventum (NYSE:SOLV) Given New $71.00 Price Target at The Goldman Sachs Group - Defense World
Mizuho Issues Positive Forecast for Solventum (NYSE:SOLV) Stock Price - Defense World
Don't Give up on the Turnaround Titan - MD+DI
Solventum Corporation (NYSE:SOLV) Q4 2024 Earnings Call Transcript - MSN
Mizuho Adjusts Price Target on Solventum to $82 From $70, Keeps Neutral Rating -March 03, 2025 at 06:32 am EST - Marketscreener.com
Solventum (NYSE:SOLV) Price Target Raised to $84.00 - Defense World
Solventum (NYSE:SOLV) Price Target Raised to $75.00 - Defense World
Nelson Peltz's Trian to push Solventum to further simplify business, WSJ reports - MSN
Positive week for Solventum Corporation (NYSE:SOLV) institutional investors who control 64% of the company - Simply Wall St
Solventum (NYSE:SOLV) Price Target Raised to $84.00 at Piper Sandler - MarketBeat
Is 3M Stock a Buy Now? - The Motley Fool
Anchor Capital Advisors LLC Sells 24,448 Shares of Solventum Co. (NYSE:SOLV) - MarketBeat
Solventum Co. (NYSE:SOLV) Holdings Cut by Pine Valley Investments Ltd Liability Co - MarketBeat
Ieq Capital LLC Acquires 14,780 Shares of Solventum Co. (NYSE:SOLV) - MarketBeat
Solventum Co. (NYSE:SOLV) Receives Consensus Recommendation of “Hold” from Analysts - Defense World
Solventum (NYSE:SOLV) Sees Large Volume IncreaseStill a Buy? - MarketBeat
Allspring Global Investments Holdings LLC Trims Stock Position in Solventum Co. (NYSE:SOLV) - MarketBeat
Handelsbanken Fonder AB Takes Position in Solventum Co. (NYSE:SOLV) - MarketBeat
Private Advisor Group LLC Boosts Stock Holdings in Solventum Co. (NYSE:SOLV) - MarketBeat
Facing tariffs and a big sale, Solventum sees profits slide - MSN
Why Solventum (SOLV) Stock Is Down Today - The Globe and Mail
Solventum (NYSE:SOLV) Price Target Raised to $85.00 at Bank of America - MarketBeat
Solventum (NYSE:SOLV) Issues Quarterly Earnings Results, Beats Expectations By $0.10 EPS - MarketBeat
What Analysts Are Saying About Solventum Stock - Benzinga India
Solventum (NYSE:SOLV) Releases FY 2025 Earnings Guidance - MarketBeat
Solventum Corp. stock falls Friday, underperforms market - MarketWatch
Solventum beats The Street in Q4 — but stock is down - Mass Device
Why Solventum (SOLV) Stock Is Down Today By Stock Story - Investing.com Canada
Thermo Fisher strikes $4.1bn deal for Solventum’s purification and filtration unit - MSN
Thermo Fisher Scientific Agreed to Acquire Solventum’s Purification and Filtration Business - Genetic Engineering & Biotechnology News
SOLV Stock Down Despite Q4 Earnings & Revenues Beat Estimates - Yahoo Finance
Solventum: Q4 EPS Beats, Cash Flow Dips - sharewise
Piper Sandler raises Solventum price target to $84, keeps neutral rating By Investing.com - Investing.com South Africa
Biotechnology company Thermo Fisher Scientific buys Solventum’s filtration and purification business for $4.1 billion - BioProcess Insider
Piper Sandler raises Solventum price target to $84, keeps neutral rating - Investing.com
Solventum, facing sagging profit, sells purification business to Thermo Fisher for $4.1 billion - MSN
Stifel Adjusts Price Target on Solventum to $88 From $82, Maintains Buy Rating -February 28, 2025 at 06:37 am EST - Marketscreener.com
Solventum (NYSE:SOLV) Stock Price Expected to Rise, Bank of America Analyst Says - Defense World
New York State Common Retirement Fund Sells 5,201 Shares of Solventum Co. (NYSE:SOLV) - MarketBeat
Solventum: Q4 Earnings Snapshot - Thehour.com
Solventum Reports Strong Revenue but EPS Declines in Q4 2024News and Statistics - IndexBox, Inc.
Solventum's Stellar Performance Puts Profit Above Forecasts - Finimize
Solventum Corporation Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2024 - Marketscreener.com
Solventum forecasts annual profit above estimates on strong surgical product sales - MSN
Truist Financial Corp Sells 3,921 Shares of Solventum Co. (NYSE:SOLV) - MarketBeat
Earnings call transcript: Solventum’s Q4 2024 earnings miss expectations, stock drops By Investing.com - Investing.com South Africa
ING Groep NV Buys New Stake in Solventum Co. (NYSE:SOLV) - MarketBeat
Solventum’s (NYSE:SOLV) Q4 Sales Top Estimates By Stock Story - Investing.com Canada
5.47%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):